Kalaris Therapeutics, Inc. (KLRS): Total Assets
$121.74M
As of 2025-12-31
$99.54M
As of 2026-06-30
-24.0%
3-year compound annual growth
-20.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $121.74M | n/m | 2026-03-17, Balance as of period end |
| 2024-12-31 | $6.16M | -96.8% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $190.80M | -31.1% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $277.08M | -3.3% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $286.59M | -22.7% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $370.82M | +166.0% | 2022-02-10, Balance as of period end |
| 2019-12-31 | $139.42M | n/a | 2021-02-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $121.74M | n/m |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $122.83M | -48.6% |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $125.19M | +17.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $113.95M | -36.5% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $130.94M | -37.5% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $134.34M | n/m |
Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗